🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I found AACR to be a remarkably enriching experience. I would like to acknowledge the following individuals: Janice M. Mehnert, M.D. Michelle Krogsgaard, PhD Amrutesh Puranik, PhD The late Jeffrey S. Weber MD PhD

Good job Teru! Thank you AACR and OncLive.com for covering our research. Special thank you to Janice Mehnert, MD and Dr. Michelle Krogsgaard for your guidance.

Congrats to Teru and Amrutesh S. Puranik on fine work! Mentoring this team brings me much joy.

NAD depletion in skeletal muscle does not compromise muscle function or accelerate aging cell.com/cell-metabolis…

Happy Birthday to this absolute LEGEND, Jeffrey Weber MD. Jeff, we miss you dearly but work to meet your example and beat cancer with the roadmap you left for us. #melanomaresearch #worktodo #immunotherapy NYU Langone Health The Angeles Clinic Moffitt Cancer Center Melanoma Research AIM at Melanoma Foundation

🧵5 Top Free Alternatives to BioRender for Scientific Illustrations! These five websites offer free scientific illustrations for biologists. Great for presentations, research papers and other research communication needs. Save and share the post!

💉Gemcitabine-nabpaclitaxel with or without tocilizumab in 1L treatment of advanced pancreatic cancer Journal of Clinical Oncology ❌ORR: 37.1% vs 35.2% ❌mPFS: 5.6 vs 5.5 mo ❌mOS: 8.4 vs 8 mo ✅18mo-OS: 27.1% vs 7% ✅Muscle loss: 43.4% vs 73.5% ⁉️IL-6 modulation for cachexia

Very interesting with IL-6R inhibition Janice Mehnert, MD Dr. Michelle Krogsgaard

What do you get the US President who just got a $400 million jet to play with? Nothing anyone but the billionaires can afford. Which brings us to the Indian-American billionaire class—specifically, the Sundar-Satya-Srinivas types. The ones who dot Silicon Valley, sparkle on

If you're an international PhD student at Harvard working on something that my lab is familiar with and you're at risk of deportation, shoot me an email. We may be able to host you or find someone else who can.

📢New paper alert in @BloodJournal We present BloodFlow, a method with an unprecedented sensitivity of 10-7 in myeloma. Another step towards meaningful assessment of #MRD in blood #mmsm Congrats Marta Carmen González Díaz-Cano PETHEMA Clínica Universidad de Navarra Cima Universidad de Navarra ashpublications.org/blood/article/…

RORγt+FoxP3+ skin-resident regulatory T cells from the periphery contribute to the therapeutic benefit of allergen immunotherapy in atopic dermatitis science.org/doi/10.1126/sc… Science Translational Medicine

Next in the #melanoma rapid oral abstract session at #ASCO25: Janice Mehnert, MD (Janice Mehnert, MD) from Perlmutter Cancer Center at NYU Langone Health presents phase II data on IL-6 receptor blocker sarilumab + Ipi/Nivo/Rela in unresectable stage III/IV melanoma. ➡️ 63.6% response rate at 24 weeks — among the

I presented data from our trial of ipi, nivo, rela and IL-6 receptor inhibitor sarilumab in metastatic melanoma. Improved response rate, and toxicity way down!Now confirming in a randomized cohort +/- sari.A patient-centered approach addressing both efficacy and tolerability.

Exercizumab?!

NEW STUDY: More than twice as many diabetic patients exposed to GLP-1 RAs (Ozempic, Wagovy, Mounjaro) developed age-related macular degeneration tinyurl.com/5a29nfh5

Yes. The time is now. Vaccines to treat and prevent cancer. jci.org/articles/view/…

Rethinking TREM2 as a target for Alzheimer’s disease after the INVOKE-2 trial failure | Nature Medicine nature.com/articles/s4159…

Immune landscape in HIV-associated lung cancers— This issue’s cover features work by Brinda Emu & team Yale Cancer Center showing the tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV: jci.org/articles/view/… The image shows

🎥Janice Mehnert, MD of Perlmutter Cancer Center at NYU Langone Health shares Phase II data on sarilumab + checkpoint blockade in unresectable melanoma. IL-6 inhibition may boost efficacy & reduce toxicity across tumor types. From #ASCO25: ➡️ow.ly/MS7H50WsxCx⬅️ ASCO #Melsm #Skcsm #ImmunoOnc #CTSM #Trial